Lifestance Health Group Stock Earnings Reports

LifeStance reported an exceptional Q1 2026: revenue grew 21% to $403M, visits rose 18% to 2.5M, and adjusted EBITDA increased 48% to $51M (12.7% margin). The clinician base expanded by 309 to ~8,349 (11% YoY) and visits per clinician increased ~7% YoY, driven by productivity initiatives. Management is expanding use of digital and AI tools (patient check-in, AI scheduling, AI-assisted documentation) and selected a new EHR with transition work beginning in 2026 and full transition in 2027. They opened six centers and completed two tuck-in acquisitions in Q1 and plan 20–30 new centers for the full year. Clinical outcomes from ~180,000 patients show ~75% had clinically significant improvement in anxiety/depression; patient satisfaction remains high (4.7/5 Google rating across >575 centers). Liquidity is healthy: $195M cash, net long-term debt $263M, net leverage 0.5x; the company deployed $49M in share repurchases under a $100M authorization. Given Q1 outperformance, full-year guidance was raised: revenue now $1.64B–$1.68B (midpoint +$25M), Center Margin $547M–$571M, and adjusted EBITDA $200M–$220M (midpoint +$15M). Management reiterated a multi-year target of mid-teens adjusted EBITDA margins by 2028 and expects mid-teens revenue growth over time. Key investor takeaways: strong top-line and margin acceleration, durable productivity improvements, disciplined M&A (tuck-ins), focused tech/AI rollout and EHR migration to scale operations, solid cash position and buyback activity, and validated clinical outcomes that support payer/referral positioning.